Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1

Oncogene

Volumn 25, Issue 16, 2006, Pages 2304-2317

  Copland, J A ^a   Marlow, L A ^a   Kurakata, S ^b   Fujiwara, K ^b   Wong, A K C ^c   Kreinest, P A ^a   Williams, S F ^a   Haugen, B R ^d   Klopper, J P ^d   Smallridge, R C ^a,d  

^a MAYO CLINIC   (United States)

^b DAIICHI SANKYO CO   (Japan)

^c Sankyo Pharma Research Institute   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Anaplastic thyroid carcinoma; Combinatorial therapy; p21WAF1 CIP1; Paclitaxel; Peroxisome proliferator activated receptor gamma; RS5444; Thiazolidinedione

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA ACTIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN P16; PROTEIN P18; PROTEIN P21; PROTEIN P27; ROSIGLITAZONE; RS 5444; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR PAX8; TROGLITAZONE; UNCLASSIFIED DRUG;

ANAPLASTIC THYROID CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; PRIORITY JOURNAL; REGULATORY MECHANISM; THYROID CARCINOMA; THYROID CELL; THYROID FOLLICULAR CARCINOMA; TRANSACTIVATION; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMANS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; FEMALE; HUMANS; MICE; PACLITAXEL; PPAR GAMMA; THIAZOLIDINEDIONES; THYROID NEOPLASMS;

ANIMALIA; MUS MUSCULUS;

EID: 33646149656     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209267     Document Type: Article

References (77)

1. Ain KB, Egorin MJ, DeSimone PA. (2000). Thyroid 10: 587-594.
2. Ain KB, Tofiq S, Taylor KD. (1996). J Clin Endocrinol Metab 81: 3650-3653.
3. Alarcon de la Lastra C, Sanchez-Fidalgo S, Villegas I, Motilva V. (2004). Curr Pharm Des 10: 3505-3524.
4. Aldred MA, Morrison C, Gimm O, Hoang-Vu C, Krause U, Dralle H et al. (2003). Oncogene 22: 3412-3416.
5. Barboule N, Chadebech P, Baldin V, Vidal S, Valette A. (1997). Oncogene 15: 2867-2875.
6. Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M et al. (2002). Thyroid 12: 953-961.
7. Belletti B, Ferraro P, Arra C, Baldassarre G, Bruni P, Staibano S et al. (1999). Oncogene 18: 4860-4869.
8. Brockman J, Gupta R, DuBois R. (1998). Gastroenterology 115: 1049-1055.
9. Castrillo A, Mojena M, Hortelano S, Bosca L. (2001). J Biol Chem 276: 34082.
10. Chang T-H, Szabo E. (2000). Cancer Res 60: 1129-1138.
11. Chang T-H, Szabo E. (2002). Clin Cancer Res 8: 1206-1212.
12. Chen F, Harrison LE. (2005). Cell Signal 17: 809-816.
13. Chung SH, Onoda N, Ishikawa T, Ogisawa K, Takenaka C, Yano Y et al. (2002). Jpn J Cancer Res 93: 1358-1365.
14. Davies GF, McFie PJ, Khandelwal RL, Roesler WJ. (2002). J Pharmacol Exp Ther 300: 72-77.
15. Debril M-B, Renaud J-P, Fajas L, Auwerx J, Debril MB, Renaud JP et al. (2001). J Mol Med 79: 30-47.
16. Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Hoog A et al. (2003). J Clin Endocrinol Metab 88: 4440-4445.
17. Eibl G, Wente MN, Reber HA, Hines OJ. (2001). Biochem Biophys Res Commun 287: 522-529.
18. Elnemr A, Ohta T, Iwata K, Ninomia I, Fushida S, Nishimura GI et al. (2000). Int J Oncol 17: 1157-1164.
19. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H et al. (1998). Proc Natl Acad Sci 95: 8806.
20. Fan S, Chang JK, Smith ML, Duba D, Fornace Jr AJ, O'Connor PM. (1997). Oncogene 14: 2127-2136.
21. Fujiwara T, Horikoshi H. (2002). Life Sci 67: 2405-2416.
22. Fujiwara T, Ohsawa T, Takahashi S, Ikeda K, Okuno A, Ushiyama S et al. (1998). Life Sci 63: 2039-2047.
23. Galli A, Ceni E, Crabb DW, Mello T, Salzano R, Grappone C et al. (2004). Gut 53: 1688-1697.
24. Girnun G, Spiegelman B. (2003). Gastroenterology 124: 564-567.
25. Gregory PJ, Wang X, Allard BL, Sahin M, Wang XL, Hay ID et al. (2004). Oncogene 23: 3634-3641.
26. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. (1999). Neoplasia 4: 330-339.
27. Han S, Sidell N, Fisher PB, Roman J. (2004). Clin Cancer Res 10: 1911-1919.
28. Hayashi N, Nakamori S, Hiraoka N, Tsujie M, Xundi X, Takano T et al. (2004). Int J Oncol 24: 89-95.
29. Hong J, Samudio I, Liu S, Abdelrahim M, Safe S. (2004). Endocrinology 145: 5774-5785.
30. Huang J-W, Shiau C-W, Yang Y-T, Kulp SK, Chen K-F, Brueggemeier RW et al. (2005). Mol Pharmacol 67: 1342-1348.
31. Itami A, Watanabe G, Shimada Y, Hashimoto Y, Kawamura J, Kato M et al. (2001). Int J Cancer 94: 370-376.
32. Kawa S, Nikaido T, Unno H, Usuda N, Nakayama K, Kiyosawa K. (2002). Pancreas 24: 1-7.
33. Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN et al. (2005). Mol Cancer Ther 4: 632-640.
34. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y. (1999). Jpn J Cancer Res 90: 75-80.
35. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR. (2004). Mol Cancer Ther 3: 1011-1020.
36. Koeffler HP. (2003). Clin Cancer Res 9: 1-9.
37. Koga H, Sakisaka S, Harada M, Takagi T, Taniguchi E, Kawaguchi T et al. (2001). Hepatology 33: 1087-1097.
38. Kroll TG, Sarraf P, Pecciarini L, Chen C-J, Mueller E, Spiegelman BM et al. (2000). Science 289: 1357-1360.
39. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S et al. (1998). Cancer Res 58: 3344-3352.
40. Li W, Fan J, Banerjee D, Bertino JR. (1999). Mol Pharmacol 55: 1088-1093.
41. Lovekamp-Swan T, Chaffin CL. (2005). Mol Cell Endocrinol 233: 15-24.
42. Lu M, Kwan T, Yu C, Chen F, Freedman B, Schafer JM et al. (2005). J Biol Chem 280: 6742-6751.
43. Lui WO, Foukakis T, Liden J, Thoppe SR, Dwight T, Hoog A et al. (2005). Oncogene 24: 1467-1476.
44. Margeli A, Kouraklis G, Theocharis S. (2003). Angiogenesis 6: 165-169.
45. Martelli ML, Iuliano R, Le Pera I, Sama' I, Monaco C, Cammarota S et al. (2002). J Clin Endocrinol Metab 87: 4728-4735.
46. McIver B, Grebe SK, Eberhardt NL. (2004). Curr Drug Targets Immune Endocr Metabol Disord 4: 221-234.
47. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. (2000). Cancer Res 60: 5558.
48. Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y et al. (2001). Gastroenterology 120: 460-469.
49. Nakashiro K, Hayashi Y, Kita A, Tamatani T, Chlenski A, Usuda N et al. (2001). Am J Pathol 159: 591.
50. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. (2001). Cancer Res 61: 6213.
51. Panigrahy D, Shen LQ, Kieran MW, Kaipainen A. (2003). Expert Opin Investigat Drugs 12: 1925-1937.
52. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ et al. (2002). J Clin Invest 110: 923-932.
53. Pei XH XY. (2005). Oncogene 24: 2787-2795.
54. Perez-Ortiz JM, Tranque P, Vaquero CF, Domingo B, Molina F, Calvo S et al. (2004). J Biol Chem 279: 8976-8985.
55. Place AE, Suh N, Williams CR, Risingsong R, Honda T, Gribble GW et al. (2003). Clin Cancer Res 9: 2798-2806.
56. Rosen ED, Spiegelman BM. (2001). J Biol Chem 276: 37731.
57. Rumi MAK, Ishihara S, Kadowaki Y, Ortega-Cava CF, Kazumori H, Kawashima K et al. (2004). Genes Cells 9: 1113-1123.
58. Sato K. (2001). Endocr J 48: 635-646.
59. Schmidt M, Lu Y, Liu B, Fang M, Mendelsohn J, Fan Z. (2000). Oncogene 19: 2423-2429.
60. Sherman SI. (2003). Lancet 361: 501-511.
61. Shiau C-W, Yang C-C, Kulp SK, Chen K-F, Chen C-S, Huang J-W et al. (2005). Cancer Res 65: 1561-1569.
62. Smith WM, Zhou XP, Kurose K, Gao X, Latif F, Kroll T et al. (2001). Hum Genet 109: 146-151.
63. Takashima T, Fujiwara Y, Higuchi K, Arakawa T, Yano Y, Hasuma T et al. (2001). Trends Mol Med 7: 395-400.
64. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M et al. (2000). Biochem Biophys Res Commun 270: 400-405.
65. Turturro F, Friday E, Fowler R, Surie D, Welbourne T. (2004). Clin Cancer Res 10: 7022-7030.
66. Vogt T, Hafner C, Bross K, Bataille F, Jauch KW, Berand A et al. (2003). Cancer 98: 2251-2256.
67. Wahl A, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW et al. (1996). Nat Med 2: 72-79.
68. Xin X, Yang S, Kowalski J, Gerritsen ME. (1999). J Biol Chem 274: 9116-9121.
69. Xu G, Pan J, Martin C, Yeung S-CJ. (2001). J Clin Endocrinol Metab 86: 1769-1777.
70. Yang H-L, Pan J-X, Sun L, Yeung S-CJ. (2003). J Clin Endocrinol Metab 88: 763-772.
71. Yang W, Velcich A, Lozonschi I, Liang J, Nicholas C, Zhuang M et al. (2005). Am J Pathol 166: 1239-1246.
72. Yang W-L, Frucht H. (2001). Carcinogenesis 22: 1379-1383.
73. Yeung S-CJ, Xu G, Pan J, Christgen M, Bamiagis A. (2000). Cancer Res 60: 650-656.
74. Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR et al. (2001). Biochem Biophys Res Commun 286: 916-922.
75. Yin F, Bruemmer D, Blaschke F, Hsueh WA, Law RE, Herle AJ. (2004). Oncogene 23: 4614-4623.
76. Yki-Jarvinen H. (2004). N Engl J Med 351: 1106-1118.
77. Yuan J, Takahashi A, Masumori N, Uchida K, Hisasue S-I, Kitamura H et al. (2005). Urology 65: 594-599.